Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability - Full Text View

Sponsored by:	Sepracor, Inc.
Information provided by:	Sepracor, Inc.
ClinicalTrials.gov Identifier:	NCT00368056

Purpose

To assess next day driving ability and psychomotor/memory function following a single night time dose of eszopiclone in insomnia patients.

Condition	Intervention	Phase
Primary Insomnia	Drug: Eszopiclone Drug: Placebo	Phase III

MedlinePlus related topics: Memory

Drug Information available for: Eszopiclone Zopiclone

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Crossover Assignment, Safety Study
Official Title:	Effects of a Single Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability and Psychomotor/Memory Function in Patients With Primary Insomnia Compared to Placebo

Further study details as provided by Sepracor, Inc.:

Primary Outcome Measures:

next day performance in a standardised test of car driving [ Time Frame: 9.5 hours post dose ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Compensatory Tracking Task (CTT) [ Time Frame: 9.5 hours post dose ] [ Designated as safety issue: No ]
Rapid Visual Information Processing (RVIP) [ Time Frame: 9.5 hours post dose ] [ Designated as safety issue: No ]
Sternberg's Short-term Memory Scanning task (STM) [ Time Frame: 9.5 hours post dose ] [ Designated as safety issue: No ]
Critical Flicker Fusion (CFF) [ Time Frame: 9.5 hours post dose ] [ Designated as safety issue: No ]
Digit Symbol Substitution Test (DSST) [ Time Frame: 9.5 hours post dose ] [ Designated as safety issue: No ]
Choice Reaction Time (CRT) [ Time Frame: 9.5 hours post dose ] [ Designated as safety issue: No ]
Leeds Sleep Evaluation Questionnaire and Leeds Analogue Rating Scales [ Time Frame: 9.5 hours post dose ] [ Designated as safety issue: No ]

Enrollment:	32
Study Start Date:	April 2005
Study Completion Date:	June 2006
Primary Completion Date:	June 2006 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental eszopiclone 3 mg	Drug: Eszopiclone eszopiclone 3 mg
2: Placebo Comparator Placebo tablet	Drug: Placebo Placebo tablet

Detailed Description:

The study is a single centre, randomised, double blind, placebo controlled 2-way crossover design in a group of 32 male and female primary insomnia patients. The medications under investigation are eszopiclone and placebo. Patients will receive the study medications and placebo on the evening of Day 2 of each treatment period. Performance will be assessed on Day 3 of each treatment period. Each treatment period will be separated by at least a 7-day washout period.

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Aged between 18 and 55 years inclusive
In good health as determined by a medical history, ECG, haematology, blood and urine biochemistry and physical examination by the doctor
Diagnostic and statistical manual of mental disorders, defined primary insomnia
A body mass index greater than or equal to 18 and less than or equal to 30
Registered with a general practitioner (GP)
Hold a full current driving licence for at least one year, and be regular car drivers

Exclusion Criteria

The use of any other medication during the study with the exception of oral, transdermal, IUDs (progestogen only contraceptive e.g. Mirena), or depot contraceptives, non-steroidal analgesics (e.g. ibuprofen), and paracetamol. A 7-day washout period is required for any patient currently receiving prescription or non-prescription sleep medication.
Diagnosed sleep disorder or confirmed symptoms other than primary insomnia (e.g. restless leg syndrome, sleep apnoea)
Significant history of mental illness, significant drug allergy, malignancy or chronic drug abuse (including alcohol)
Any subject with known hypersensitivity to any of the study treatments
A sleep/wake cycle other than primary insomnia (e.g. shift work) liable to prejudice the results of the study
Pregnant or lactating females, and females of child bearing potential not using effective contraception
Patients who habitually smoke more than 5 cigarettes per day
Caffeine consumption of more than 5 cups or glasses per day
History of alcohol or drug dependence or intake of more than the equivalent of 14 units of alcohol per week for females and 21 units per week for males
Current participation in another clinical trial, or participation in a clinical trial within the last 90 days

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00368056

Locations

United Kingdom, Surrey
HPRU Medical Research Centre, University of Surrey
Guildford, Surrey, United Kingdom

Sponsors and Collaborators

Sepracor, Inc.

More Information

Responsible Party:	Sepracor Inc. ( Eszopiclone Medical Director )
Study ID Numbers:	190-060
Study First Received:	August 23, 2006
Last Updated:	October 9, 2008
ClinicalTrials.gov Identifier:	NCT00368056
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Sleep Initiation and Maintenance Disorders
Zopiclone
Mental Disorders

Dyssomnias
Sleep Disorders
Sleep Disorders, Intrinsic

Additional relevant MeSH terms:

Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009